Molecular Differences and Similarities between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis
Year: 2013
Type: article
Abstract: Transgenic (Tg) mouse models of Alzheimer's disease (AD) have been extensively used to study the pathophysiology of this dementia and to test the efficacy of drugs to treat AD. The 5XFAD Tg mouse, which contains two presenilin-1 and three amyloid precursor protein (APP) mutations, was designed to rapidly recapitulate a portion of the pathologic alterations present in human AD. APP and its proteolytic peptides, as well as apolipoprotein E and endogenous mouse tau, were investigated in the 5XFAD mice at 3 months, 6 months, and 9 months. AD and nondemented subjects were used as a frame of reference. APP, amyloid-beta (Aβ) peptides, APP C-terminal fragments (CT99, CT83, AICD), β-site APP-cleaving enzyme, and APLP1 substantially increased with age in the brains of 5XFAD mice. Endogenous mouse tau did not show age-related differences. The rapid synthesis of Aβ and its impact on neuronal loss and neuroinflammation make the 5XFAD mice a desirable paradigm to model AD.
Source: Biochemistry Insights
DOI: 10.4137/bci.s13025
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: BACE1 as a Therapeutic Target for Alzheimer's Disease, APP/AB/Tau biochemistry in transgenic mice, familial and sporadic AD, Molecular Neuropathology and Mechanisms of BACE1 Elevation in Alzheimer's Disease, BACE1 as a Therapeutic Target for Alzheimer's Disease, Arizona Alzheimer's Disease Core Center, National Brain and Tissue Resource for Parkinson's Disease and Related Disorders
OpenAlex ID: W2001436892